# W. Schuyler Jones

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/w-schuyler-jones/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,486 |
| Field | Peripheral Artery Disease Management |
| h-index | 59 |
| i10-index | 182 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5006133112 |
| ORCID iD | https://orcid.org/0000-0002-7288-9596 |
| Works | 378 |

## Researcher papers

- [2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines](https://scholariq.org/papers/2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines](https://scholariq.org/papers/2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the/)
- [2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease](https://scholariq.org/papers/2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease/)
- [Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study](https://scholariq.org/papers/safety-of-the-oral-factor-xia-inhibitor-asundexian-compared-with-apixaban-in/)
- [Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease](https://scholariq.org/papers/comparative-effectiveness-of-aspirin-dosing-in-cardiovascular-disease/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease](https://scholariq.org/papers/2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-2/)

## Researcher topics

- [Peripheral Artery Disease Management](https://scholariq.org/topics/peripheral-artery-disease-management/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Cerebrovascular and Carotid Artery Diseases](https://scholariq.org/topics/cerebrovascular-and-carotid-artery-diseases/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.